Regulatory role of CD39 and CD73 in tumor immunity.
Future Oncol
; 20(19): 1367-1380, 2024.
Article
en En
| MEDLINE
| ID: mdl-38652041
ABSTRACT
CD39 is the rate-limiting enzyme for the molecular signal cascade leading to the generation of ADP and adenosine monophosphate (AMP). In conjunction with CD73, CD39 converts adenosine triphosphate (ATP) to ADP and AMP, which leads to the accumulation of immunosuppressive adenosine in the tumor microenvironment. This review focuses on the role of CD39 and CD73 in immune response and malignant progression, including the expression of CD39 within the tumor microenvironment and its relationship to immune effector cells, and its role in antigen presentation. The role of CD39- and CD73-targeting therapeutics and cancer-directed clinical trials investigating CD39 modulation are also explored.
[Box see text].
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Apirasa
/
5'-Nucleotidasa
/
Microambiente Tumoral
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos